Shire is developing a recombinant enzyme replacement therapy produced in human cell lines, currently in phase III. They partnered with Amicus in order to develop the oral chaperone Plicera, which works in a different way (by binding to the mutant enzyme to enhance trafficking to the lysosome). Results from Plicera's 6-month phase II study, are expected in 3Q08. Plicera is potentially a less expensive and more convenient therapy than ERT, and may have the advantage of crossing the BBB and treating Types 2 and 3 patients. Shire obviously believes in the chaperone approach as they teamed up with Amicus on another one - Amigal for Fabry disease.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.